Novartis (NVS)

The latest reported annual results, for the fiscal year ending in December, show stronger sales and improved operating profitability compared with the preceding fiscal year. Novartis increased research spending at the same time, so the improvement did not depend on cutting its drug-development budget.

Massive's annual statements also show higher net income and cash from operations. These are annual results; a recent quarterly result is not available for assessment here.

Novartis develops, manufactures and sells medicines worldwide.

We like the powerful combination of an established medicines business and an ambitious drug-development engine. Its strongest opportunity is to build lasting treatment franchises across cancer, immune disorders, neuroscience and cardiovascular, kidney and metabolic disease. A global commercial presence gives that scientific ambition a platform to reach patients.

The portfolio also includes off-patent medicines, making Novartis more than a business built solely around new discoveries. It earns revenue by selling its products globally, with the United States an important market.

Annual revenue increased from the preceding fiscal year, but product and geographic growth breakdowns are unavailable. The consolidated results therefore do not establish which treatment area drove the increase.

Research and development spending rose, showing a larger commitment to the work behind new medicines. The opportunity lies in translating that work into commercially successful treatments. The available evidence does not identify individual development programs, clinical milestones or approval outcomes.

Gross margin improved compared with the preceding fiscal year, meaning Novartis retained more of its sales after the reported cost of producing its medicines. Operating margin also widened as total operating expenses grew more slowly than revenue.

Research and selling expenses increased, while other operating expenses declined. This combination supports the reported improvement, but the statements do not explain the underlying product mix, pricing or individual expense changes.

Net income attributable to common shareholders increased compared with the preceding fiscal year. Diluted earnings per share also rose, helped by a lower reported diluted share count. The statements do not establish why the share count declined.

The latest annual earnings improvement was supported by higher operating income, rather than a larger net contribution from items outside operations. Interest expense and income taxes both increased. Earlier annual results included discontinued operations, which makes a simple long-term comparison of bottom-line profit less informative.

Cash from operations increased and exceeded consolidated net income in the latest fiscal year. That provides tangible support for reported profit. Changes in operating assets and liabilities absorbed more cash than in the preceding fiscal year, showing that day-to-day funding needs also increased.

Novartis spent more on property, plant and equipment, while its overall investing cash outflow declined. Operations covered equipment purchases and dividends, but broader investing and financing outflows exceeded operating cash generation before net borrowing. Other investing and financing categories are not detailed enough to identify specific acquisitions or shareholder transactions.

Year-end cash was broadly stable, and current assets exceeded current liabilities. Reported current debt declined, although total liabilities increased. The cash-flow statement records net long-term borrowing, showing that borrowing contributed to the year's funding.

The balance-sheet data do not separately identify long-term debt within the latest noncurrent liabilities, so they cannot support a complete debt assessment. Goodwill and intangible assets are also important balance-sheet items. These represent accounting values rather than available cash, and their durability matters if the associated businesses or assets underperform.

The current analyst targets and SPY comparison are shown in Our verdict.

Watch whether increased research spending produces identifiable clinical and commercial milestones. The development portfolio offers a meaningful opportunity, but the available evidence does not establish the success of individual programs. Competition in off-patent franchises remains a business risk to monitor.

Also watch how Novartis balances investment and shareholder payments with internally generated cash. Clearer disclosure of long-term debt and the larger investing and financing categories would help explain the funding burden behind an otherwise strong operating business.